THE ASSOCIATION OF BODY MASS INDEX (BMI) AND HEIGHT WITH ONCOTYPE DX SCORES IN WOMEN WITH HORMONE RECEPTOR POSITIVE HER 2 NEGATIVE BREAST CANCER IN THE NYC METROPOLITAN AREA gsirnioti@gmail.com

3103-03

THE ASSOCIATION OF BODY MASS INDEX (BMI) AND HEIGHT WITH ONCOTYPE DX SCORES IN WOMEN WITH HORMONE RECEPTOR POSITIVE HER 2 NEGATIVE BREAST CANCER IN THE NYC METROPOLITAN AREA

10

Lisa Newman lan4002@med.cornell.edu Weill Cornell Medicine New York United States

Tammy Ju taj9062@med.cornell.edu New York Presbyterian Queens Queens United States

United States

Oral or Poster

The purpose of this study was to examine the association of BMI and height with the clinicopathological characteristics and outcomes of females with breast cancer and Oncotype Dx score in the New York State population.

We conducted a retrospective study of female patients with hormone receptor positive, HER 2 negative breast cancer who underwent breast surgery identified from the Tumor Registry of Weill Cornell Medicine between 2010 and 2023.Patients without Oncotype Dx score and stage IV patients were excluded.

1,435 breast cancer patients were identified with a mean follow-up of 3.83+/-3.3 years. The median BMI was 24.65 (21.92, 28.41) and the median height in meters was 1.63 (1.57, 1.68). BMI was found to have a statistically significant positive association with tumor size (p<0.001) and age (p<0.001) and negative correlation with Oncotype Dx score (p=0.009). Height was not associated with Oncotype Dx score (p = 0.98). Tumor size was larger in taller female patients (p = 0.066). Height had a statistically significant negative correlation with age at diagnosis (P<0.001). No association was noted between height and nodal stage (p=0.81). Patients with increased BMI had a higher probability of having poorly differentiated tumors (p=0.008). On multivariable analysis, after adjusting for stage and Oncotype Dx score, no difference was seen between time to locoregional or metastatic recurrence and BMI or height.

Breast cancer patients with higher BMIs are associated with larger T-stage and more poorly differentiated tumors. Increased BMI is associated with clinically poorer breast tumor features which suggests worse clinical outcomes.